首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1671847

自體細胞治療市場：按產品類型、按應用、按技術、按最終用戶、按地區

Autologous Cell Therapy Market, By Product Type, By Application, By Technology, By End User, By Geography

出版日期: 2025年01月07日 | 出版商:

Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025年全球自體細胞治療市場規模估計為 55.1億美元，預計到2032年將達到 223億美元，2025-2032年的年複合成長率為 22.1%。

報告範圍		報告詳細資訊
基準年	2024	2025年市場規模	55.1億美元
歷史資料	從2020年到2024年	預測期	2025 至2032年
預測期：2025-2032年年複合成長率：	22.10％	2032年價值預測	223億美元

圖表.2025年自體細胞治療市場佔有率（%）（依地區）

近年來，全球自體細胞治療市場經歷了顯著成長。自體細胞療法包括從患者自身體內提取幹細胞或其他類型的細胞，透過各種過程進行修改或擴增，然後將其注射回同一患者體內以治療疾病。它提供了一種治療癌症和神經系統疾病等複雜疾病的替代治療方法，同時最大限度地減少免疫抗原性問題。慢性病盛行率的上升、個人化醫療的需求不斷成長以及自體細胞相對於同種異體細胞的優勢是預計未來推動自體細胞治療需求的主要因素。然而，與市場開發和製造相關的高成本和監管挑戰對市場構成了重大障礙。

市場動態：

全球自體細胞治療市場受到以下因素的推動：老年人口不斷增加，更容易患上慢性病；公共和私營公司對產品開發的投資不斷增加；以及對個人化治療方案的需求不斷成長。然而，預計高昂的開發成本、複雜的製造流程以及嚴格的監管政策將在預測期內抑制市場成長。目前進行各種臨床試驗，以評估自體細胞療法針對新適應症的有效性和安全性，創新製造技術的開發為現有企業和新參與企業創造了龐大的商機。主要企業與學術研究機構合作，擴大這些治療方法的應用。由於中國和印度等主要國家的醫療保健基礎設施不斷增強以及醫療保健支出不斷增加，亞太地區提供了有利的市場機會。

本研究的主要特點

本報告對全球自體細胞治療市場進行了詳細分析，並以2024年為基準年，展示了預測期（2025-2032年）的市場規模和年複合成長率。

強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。

提供關於市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。

全球自體細胞治療市場的主要企業根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行分析。

主要公司包括Bristol Myers Squibb、Novartis、Gilead Sciences、Kite Pharma、Celgene、Amgen、Takeda Pharmaceutical Company、Merck KGaA、Bluebird Bio、Celyad Oncology、Adaptimmune Therapeutics、Allogene Therapeutics、Athersys, Inc.、BrainStorm Cell Therapeutics、Sorrento Therapeutics。

本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。

本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

相關人員將透過用於分析全球自體細胞治療市場的各種策略矩陣更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 5.51 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	22.10%	2032 Value Projection:	USD 22.30 Bn

The global autologous cell therapy market has been witnessing significant growth in the recent years. Autologous cell therapy involves the collection of stem cells or other types of cells from patient's own body, modifying or expanding them through various processes and infusing back to the same patient to treat diseases. It provides an alternative therapeutic approach to treat complex diseases like cancer and neurological disorders with minimal immunogenicity concerns. Rising prevalence of chronic diseases, growing demand for personalized medicine, and advantages of autologous cells over allogeneic cells are some key factors expected to propel demand for autologous cell therapies going forward. However, high costs associated with development and manufacturing along with regulatory challenges are major barriers to the market.

Market Dynamics:

The global autologous cell therapy market is driven by rising geriatric population vulnerable to develop chronic diseases, increasing investments from public and private players to expedite product development, and growing demand for personalized treatment options. However, high development costs, complex manufacturing processes, and stringent regulatory policies are projected to restrain the market growth during the forecast period. Various ongoing clinical trials evaluating efficacy and safety of autologous cell therapies for new indications and development of innovative manufacturing technologies present significant opportunities for existing as well as new market players. Key players are collaborating with academic research institutions to expand applications of these therapies. Asia Pacific presents lucrative market opportunities with growing healthcare infrastructure and increasing healthcare spending in major countries like China and India.

Key Features of the Study:

This report provides in-depth analysis of the global autologous cell therapy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autologous cell therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Bristol Myers Squibb, Novartis, Gilead Sciences, Kite Pharma, Celgene, Amgen, Takeda Pharmaceutical Company, Merck KGaA, Bluebird Bio, Celyad Oncology, Adaptimmune Therapeutics, Allogene Therapeutics, Athersys, Inc., BrainStorm Cell Therapeutics, and Sorrento Therapeutics

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global autologous cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autologous cell therapy market

Market Segmentation

Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Cell-based therapies
- Tissue-based therapies
- Gene therapies
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Cardiovascular diseases
- Neurological disorders
- Orthopedic disorders
- Autoimmune diseases
- Wound healing
Technology Insights (Revenue, USD Bn, 2020 - 2032)
- Stem cell therapy
- CAR T-cell therapy
- T-cell receptor (TCR) therapy
- Induced pluripotent stem cells (iPSCs)
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Research institutes
- Biotechnology companies
- Pharmaceutical companies
- Others
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Bristol Myers Squibb
- Novartis
- Gilead Sciences
- Kite Pharma
- Celgene
- Amgen
- Takeda Pharmaceutical Company
- Merck KGaA
- Bluebird Bio
- Celyad Oncology
- Adaptimmune Therapeutics
- Allogene Therapeutics
- Athersys, Inc.
- BrainStorm Cell Therapeutics
- Sorrento Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Autologous Cell Therapy Market, By Product Type
- Global Autologous Cell Therapy Market, By Application
- Global Autologous Cell Therapy Market, By Technology
- Global Autologous Cell Therapy Market, By End User
- Global Autologous Cell Therapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Autologous Cell Therapy Market, By Product Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cell-based therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Tissue-based therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Gene therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Autologous Cell Therapy Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiovascular diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Neurological disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Orthopedic disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autoimmune diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Wound healing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Autologous Cell Therapy Market, By Technology, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Stem cell therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
CAR T-cell therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
T-cell receptor (TCR) therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Induced pluripotent stem cells (iPSCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Autologous Cell Therapy Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Research institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Biotechnology companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pharmaceutical companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Autologous Cell Therapy Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kite Pharma
Celgene
Amgen
Takeda Pharmaceutical Company
Merck KGaA
Bluebird Bio
Celyad Oncology
Adaptimmune Therapeutics
Allogene Therapeutics
Athersys, Inc.
BrainStorm Cell Therapeutics
Sorrento Therapeutics

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

自體細胞治療市場規模、佔有率、趨勢分析報告：按治療類型、治療領域、地區、細分預測，2025-2030 年

自體細胞治療市場：按來源、適應症和最終用戶分類 - 2025-2030 年全球預測

全球自體細胞治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

自體細胞治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按來源、應用、最終用戶、地區和競爭細分，2019-2029F

FAQ

自體細胞治療市場：按產品類型、按應用、按技術、按最終用戶、按地區